gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Telotristat Ethyl

            Therapeutic Area: Gastroenterology Product Name: Xermelo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $62.5 million Upfront Cash: $41.0 million

            Deal Type: Agreement September 23, 2020

            Details:

            With this agreement including the repayment of Lexicon’s secured loan concurrent with the closing of its sale of XERMELO®, Lexicon will have reduced the principal amount of its outstanding debt, supporting advancement of its LX9211 neuropathic pain program and other trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Crofelemer

            Therapeutic Area: Gastroenterology Product Name: Mytesi

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oasis Capital

            Deal Size: $2.3 million Upfront Cash: Undisclosed

            Deal Type: Agreement September 10, 2020

            Details:

            Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi® drug product to Cardinal Health for the period of August 11, 2020 through September 3, 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Certolizumab Pegol

            Therapeutic Area: Gastroenterology Product Name: Cimzia

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: UCB Pharma S.A.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 18, 2020

            Details:

            The outcomes-based agreement for the CIMZIA lyophilized powder healthcare professional administered formulation applies to all commercial members in Highmark's national and core health insurance markets in Pennsylvania, West Virginia, and Delaware.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Elobixibat

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hercules Capital

            Deal Size: $105.0 million Upfront Cash: $10.0 million

            Deal Type: Financing June 09, 2020

            Details:

            These funding arrangements with new and existing partners provide the company additional flexibility and cash runway into the beginning of 2022, past the planned approval and commercial launch of odevixibat for the treatment of progressive familial intrahepatic cholestasis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ustekinumab

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 16, 2020

            Details:

            Scottish Medicines Consortium has accepted Janssen Pharmaceutical’s Stelara for use on the National Health Service Scotland to treat moderately to severely active ulcerative colitis (UC) in adults.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eravacycline

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: AcelRx Pharmaceuticals

            Deal Size: $26.9 million Upfront Cash: Undisclosed

            Deal Type: Acquisition March 16, 2020

            Details:

            Tetraphase and AcelRx entered into a co-promotion agreement to market and promote XERAVA™ for the treatment of complicated intra-abdominal infections and DSUVIA® for the treatment of acute pain.